SCHEMBL23632467

SCHEMBL23632467

O=C(O)c1ccc(N2C[C@@H](Oc3ccc(C(F)(F)F)cc3)C[C@H]2COC(F)(F)F)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKAA2 P54646 1/20 0.42
ACACB O00763 1/20 0.40
EPHX2 P34913 2/20 0.39
GRM4 Q14833 1/20 0.38
LIPG Q9Y5X9 4/20 0.37
LPL P06858 1/20 0.37
ADRB2 P07550 1/20 0.36
TACR1 P25103 1/20 0.36
TACR3 P29371 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
GCGR P47871 2/20 0.35
GCG P01275 1/20 0.35
RET P07949 1/20 0.35
LIPC P11150 1/20 0.35
LTA4H P09960 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.34
SCN9A Q15858 2/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23632833 0.91 PRKAA2 (0.41) PRKAA2ACACBEPHX2GRM4LIPG
SCHEMBL23633131 0.91 PRKAA2 (0.41) PRKAA2ACACBEPHX2GRM4LIPG
SCHEMBL28592946 0.90 ACACB (0.42) PRKAA2ACACBEPHX2GRM4ADRB2
SCHEMBL23632193 0.89 PRKAA2 (0.41) PRKAA2ACACBEPHX2GRM4LIPG
SCHEMBL23632629 0.89 PRKAA2 (0.41) PRKAA2ACACBEPHX2GRM4LIPG
SCHEMBL23632206 0.89 EPHX2 (0.39) PRKAA2ACACBEPHX2GRM4LIPG
SCHEMBL23632894 0.89 EPHX2 (0.39) PRKAA2ACACBEPHX2GRM4LIPG
SCHEMBL23632766 0.88 PRKAA2 (0.41) PRKAA2ACACBEPHX2GRM4LIPG
SCHEMBL23632295 0.86 PRKAA2 (0.42) PRKAA2ACACBEPHX2GRM4LIPG
SCHEMBL23632397 0.85 EPHX2 (0.45) EPHX2LIPGADRB2LIPCLTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230067159-A1 ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2023-03-02 US disclosed
EP-4089079-A1 ROR GAMMA T INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2022-11-16 EP disclosed
WO-2021139599-A1 RORγT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 东莞市东阳光新药研发有限公司 2021-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230067159-A1 ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF RORC, RORB, RORA PRKAA2 1639/4885ACACB 2723/4885EPHX2 1247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.